ViiV Healthcare
Five Moore Drive
Research Triangle Park
North Carolina
27709-3398
United States
Tel: 877-844-8872
Website: http://www.viivhealthcare.com/
135 articles about ViiV Healthcare
-
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Use of Dovato in Virologically Suppressed Adults with HIV-1
10/16/2019
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the submission of a supplemental New Drug Application to the US Food and Drug Administration for Dovato as a switch treatment for HIV-1 infection in virologically suppressed adults on a stable antiretroviral regimen with no treatment failure.
-
Clinical Catch-up for August 19-23
8/26/2019
Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week. -
ViiV Healthcare Reports Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-Treatment Regimen Administered Every Two Months
8/22/2019
ATLAS-2M study met its primary endpoint, showing similar efficacy of cabotegravir and rilpivirine administered every eight weeks compared to four-week administration
-
ViiV Healthcare’s two-month injection proved to be as effective as monthly injections for HIV treatment that are currently on the market, the GlaxoSmithKline subsidiary said this morning as it continues to position itself for a leading share of the market alongside Gilead Sciences.
-
ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance
7/24/2019
ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced Week 96 results from its phase III GEMINI 1 & 2 studies,
-
ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection
7/24/2019
Today ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced that data from the phase III TANGO study showed that the 2-drug regimen (2DR) of Dovato▼ (dolutegravir/lamivudine) has similar efficacy to a tenofovir alafenamide fumarate (TAF)-containing regimen of at least three drugs in virally supressed and stable adults with HIV-1
-
ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019
7/22/2019
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 96 results from the phase III BRIGHTE study of investigational fostemsavir in heavily treatment-experienced adults with HIV-1 infection.
-
Acacia's founder will continue on in an advisory role while ViiV's departing CSO is eying multiple opportunities.
-
Clinical Catch-Up for July 8-12
7/15/2019
It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look. -
ViiV Healthcare Announces Phase III Study Meets Primary Endpoint, Demonstrating the Ability to Control HIV-1 With the 2-drug Regimen Dovato in Virally Suppressed Patients Switching From a TAF-containing, 3-drug Regimen
7/10/2019
Week 48 results from the TANGO study will be presented this month at 10th International AIDS Society Conference on HIV Science (IAS 2019)
-
The two-drug combination of Dovato provided similar long-term viral suppression to common three-drug regimens.
-
Legal Decision Could Open the Doors for Truvada Generic Competition One Year Early, Gilead Says
5/13/2019
Gilead's Truvada is expected to lose patent protection in 2021, but a recent court decision in Europe could change that. -
ViiV Healthcare Submits New Drug Application to US FDA for the First Monthly, Injectable, Two-Drug Regimen of Cabotegravir and Rilpivirine for Treatment of HIV
4/29/2019
If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV
-
The NDA was based on positive Phase III data that shows the once-a-month treatment is as effective as the daily standard of care.
-
The survey showed that not surprisingly, patients by and large have negative views of the pharma industry when it comes to corporate responsibility and pricing -- mostly pricing.
-
The U.S. Food and Drug Administration (FDA) approved ViiV Healthcare’s Dovato, a once-a-day, single-tablet combination of dolutegravir (DTG) and lamivudine (3TC) for HIV-1 in adults who had not received treatment before.
-
US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults
4/8/2019
Approval based on GEMINI pivotal trials in which Dovato achieved non-inferior efficacy compared to a dolutegravir-based, traditional, three-drug regimen through 48 weeks, with no cases of resistance1
-
ViiV Healthcare, presented three-year data from the SWORD 1 and 2 clinical trials in HIV. The data was presented at the 25th Annual Conference of the British HIV Association (BHIVA) in Bournemouth, UK.
-
Often, patients prefer oral medications over receiving an injection or infusion, but daily pills sometimes result in compliance problems. In the case of this combination injection, it would, if approved, require patients to visit a clinic or physician once a month for the shot.
-
ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies Showing Long-Acting, Injectable Two-Drug Regimen of Cabotegravir and Rilpivirine Has Similar Efficacy to Daily
3/7/2019
Comprehensive data from ATLAS and FLAIR studies presented at the 2019 Conference on Retroviruses and Opportunistic Infections show investigational long-acting injectable to be effective in maintaining viral suppression